| Structural basis for the autoinhibition of c-Abl tyrosine kinase B Nagar, O Hantschel, MA Young, K Scheffzek, D Veach, W Bornmann, ... Cell 112 (6), 859-871, 2003 | 1125 | 2003 |
| Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets U Rix, O Hantschel, G Dürnberger, LL Remsing Rix, M Planyavsky, ... Blood, The Journal of the American Society of Hematology 110 (12), 4055-4063, 2007 | 817 | 2007 |
| Regulation of the c-Abl and Bcr–Abl tyrosine kinases O Hantschel, G Superti-Furga Nature reviews Molecular cell biology 5 (1), 33-44, 2004 | 699 | 2004 |
| A myristoyl/phosphotyrosine switch regulates c-Abl O Hantschel, B Nagar, S Guettler, J Kretzschmar, K Dorey, J Kuriyan, ... Cell 112 (6), 845-857, 2003 | 623 | 2003 |
| An efficient tandem affinity purification procedure for interaction proteomics in mammalian cells T Bürckstümmer, KL Bennett, A Preradovic, G Schütze, O Hantschel, ... Nature methods 3 (12), 1013-1019, 2006 | 502 | 2006 |
| The DEAD‐box helicase DDX3X is a critical component of the TANK‐binding kinase 1‐dependent innate immune response D Soulat, T Bürckstümmer, S Westermayer, A Goncalves, A Bauch, ... The EMBO journal 27 (15), 2135-2146, 2008 | 407 | 2008 |
| The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib O Hantschel, U Rix, U Schmidt, T Bürckstümmer, M Kneidinger, G Schütze, ... Proceedings of the National Academy of Sciences 104 (33), 13283-13288, 2007 | 365 | 2007 |
| Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells LL Remsing Rix, U Rix, J Colinge, O Hantschel, KL Bennett, T Stranzl, ... Leukemia 23 (3), 477-485, 2009 | 345 | 2009 |
| Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib O Hantschel, U Rix, G Superti-Furga Leukemia & lymphoma 49 (4), 615-619, 2008 | 343 | 2008 |
| Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase B Nagar, O Hantschel, M Seeliger, JM Davies, WI Weis, G Superti-Furga, ... Molecular cell 21 (6), 787-798, 2006 | 284 | 2006 |
| c-Abl phosphorylates α-synuclein and regulates its degradation: implication for α-synuclein clearance and contribution to the pathogenesis of Parkinson's disease AL Mahul-Mellier, B Fauvet, A Gysbers, I Dikiy, A Oueslati, S Georgeon, ... Human molecular genetics 23 (11), 2858-2879, 2014 | 283 | 2014 |
| Structural coupling of SH2-kinase domains links Fes and Abl substrate recognition and kinase activation P Filippakopoulos, M Kofler, O Hantschel, GD Gish, F Grebien, E Salah, ... Cell 134 (5), 793-803, 2008 | 246 | 2008 |
| BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia O Hantschel, W Warsch, E Eckelhart, I Kaupe, F Grebien, KU Wagner, ... Nature chemical biology 8 (3), 285-293, 2012 | 241 | 2012 |
| Charting the molecular network of the drug target Bcr-Abl M Brehme, O Hantschel, J Colinge, I Kaupe, M Planyavsky, T Köcher, ... Proceedings of the National Academy of Sciences 106 (18), 7414-7419, 2009 | 230 | 2009 |
| A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domain J Wojcik, O Hantschel, F Grebien, I Kaupe, KL Bennett, J Barkinge, ... Nature structural & molecular biology 17 (4), 519-527, 2010 | 218 | 2010 |
| Structure, regulation, signaling, and targeting of abl kinases in cancer O Hantschel Genes & cancer 3 (5-6), 436-446, 2012 | 206 | 2012 |
| Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis F Grebien, O Hantschel, J Wojcik, I Kaupe, B Kovacic, AM Wyrzucki, ... Cell 147 (2), 306-319, 2011 | 186 | 2011 |
| Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348) T Zhou, S Georgeon, R Moser, DJ Moore, A Caflisch, O Hantschel Leukemia 28 (2), 404-407, 2014 | 148 | 2014 |
| Differential signaling networks of Bcr–Abl p210 and p190 kinases in leukemia cells defined by functional proteomics S Reckel, R Hamelin, S Georgeon, F Armand, Q Jolliet, D Chiappe, ... Leukemia 31 (7), 1502-1512, 2017 | 129 | 2017 |
| The growing arsenal of ATP-competitive and allosteric inhibitors of BCR–ABL O Hantschel, F Grebien, G Superti-Furga Cancer research 72 (19), 4890-4895, 2012 | 120 | 2012 |
